Latest Information Update: 21 Nov 2006
At a glance
- Originator Arachnova
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Pulmonary fibrosis
Most Recent Events
- 21 Nov 2006 Preclinical development is still ongoing
- 02 Jul 2003 Preclinical trials in Pulmonary fibrosis in United Kingdom (unspecified route)